Neal D E, Mellon K
Department of Urology, Freeman Hospital, University of Newcastle upon Tyne, UK.
Urol Int. 1992;48(4):365-71. doi: 10.1159/000282357.
Recently, expectations have been raised that molecular biological studies of human tumours may be of value in helping to predict future clinical behaviour, in terms of therapeutic response and long-term survival. The epidermal growth factor receptor (EGFr) is a cell surface receptor for EGF and transforming growth factor-alpha which is overexpressed by a number of human tumours. This article principally reviews previous investigations of the role of the epidermal growth factor receptor in bladder cancer and examines methods of detection, the correlation between EGFr status and known prognostic indicators and the value of assessing EGFr status in predicting clinical outcome in patients with bladder cancer. Recent studies of the c-erbB-2 proto-oncogene in bladder cancer and of cell cycling using Ki-67 are included.
最近，人们对人类肿瘤的分子生物学研究寄予厚望，期望其在帮助预测未来临床行为（包括治疗反应和长期生存）方面具有价值。表皮生长因子受体（EGFr）是表皮生长因子（EGF）和转化生长因子-α的细胞表面受体，在许多人类肿瘤中过度表达。本文主要回顾了以往关于表皮生长因子受体在膀胱癌中作用的研究，并探讨了检测方法、EGFr状态与已知预后指标之间的相关性，以及评估EGFr状态对预测膀胱癌患者临床结局的价值。还纳入了最近关于膀胱癌中c-erbB-2原癌基因和使用Ki-67进行细胞周期分析的研究。
